Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.

International journal of molecular sciences - 13 Jun 2021

Lee Jui-Hao, Lin Si-Yin, Liu Jen-Wei, Lin Shinn-Zong, Harn Horng-Jyh, Chiou Tzyy-Wen

Abstract excerpt

Spinocerebellar ataxia type 3 (SCA3), a hereditary and lethal neurodegenerative disease, is attributed to the abnormal accumulation of undegradable polyglutamine (polyQ), which is encoded by mutated ataxin-3 gene (ATXN3). The toxic fragments processed from mutant ATXN3 can induce neuronal death, leading to the muscular incoordination of the human body. Some treatment strategies of SCA3 are preferentially focused...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylate Kinase
Share to Ataxin-3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autophagy

Share to Cerebellum

Share to Machado-Joseph Disease

Share to Protein Aggregates

Share to Purkinje Cells

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 34199295
DOI: 10.3390/ijms22126339
PMCID: PMC8231882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.PMID 34199295Read ↗

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to TherapeuticsSemantic proximity Read ↗

Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapySemantic proximity Read ↗

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3.Semantic proximity Read ↗

p62, the Receptor for Selective Autophagy, Contributes in ATXN3 Aggregate Formation in Spinocerebellar Ataxia Type 3Semantic proximity Read ↗

Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem CellsSemantic proximity Read ↗

Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapySemantic proximity Read ↗

Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells.Semantic proximity Read ↗

Recent therapeutic prospects for Machado–Joseph diseaseSemantic proximity Read ↗

Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado–Joseph Disease through Integration of Pathological Biomarkers and Therapeutic StrategiesSemantic proximity Read ↗

Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.Semantic proximity Read ↗

Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in Spinocerebellar Ataxia Type 3.Semantic proximity Read ↗

Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.